News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ampio Pharmaceuticals, Inc. (AMPE) Completes Enrollment And Dosing In 2nd Pivotal Clinical Trial For Ampion™ (The STEP Study) For Its FDA Biological License Application (BLA)


2/18/2014 9:47:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GREENWOOD VILLAGE, Colo.
, Feb. 18, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it has completed enrollment and dosing of 500 patient in the pivotal trial of Ampion for the treatment of acute osteoarthritis of-the-knee (OAK). http://clinicaltrials.gov/ct2/show/NCT02024529?term=ampio&rank=1

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, explained: "This phase III, final pivotal clinical trial is a randomized, placebo (vehicle) controlled, double-blind study in which 500 patients with osteoarthritis (OA) of the knee were randomized to 4 ml intra-articular injection of Ampion, or a 4 ml saline vehicle control. Similar to the initial pivotal trial (SPRING study) the primary end point is at 12 weeks, with a follow up evaluation at 20 weeks. The clinical effects of treatment on OA pain will be evaluated during clinic visits at 6, 12 and 20 weeks using WOMACR osteoarthritis index and Patient's Global Assessment (PGA) of disease severity. Patient safety will be monitored by recording adverse events, concomitant medications, physical examination, vital signs and laboratory tests. In addition, a parallel study of a subpopulation of the patients will be subjected to Magnetic Resonance Imaging (MRI) and testing of serum and synovial fluid biomarkers to evaluate signs of knee cartilage regeneration."

Ampio CEO Michael Macaluso reported that: "The Company is on track to complete this final Ampion clinical trial within the timeline previously announced and we expect to file the BLA later this year. The manufacturing facility is expected to begin production of test batches of Ampion early this summer."

About Osteoarthritis
Osteoarthritis is the most common form of arthritis, affecting over 27 million people in the United States. It is a progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone. The incidence of developing osteoarthritis of the knee or hip over a lifetime is approximately 46% and 25%, respectively. Certain risk factors in conjunction with natural wear and tear lead to the breakdown of cartilage. Osteoarthritis is caused by inflammation of the soft tissue and bony structures of the joint, which worsens over time and leads to progressive thinning of articular cartilage. Other symptoms include narrowing of the joint space, synovial membrane thickening, osteophyte formation and increased density of subchondral bone.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact: April Ramirez, aramirez@ampiopharma.com, Ampio Pharmaceuticals, Inc.(720) 437-6500,

SOURCE Ampio Pharmaceuticals, Inc.



Help employers find you! Check out all the jobs and post your resume.
Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES